國立虎尾科技大學 |

Pathogenesis of Systemic Lupus Erythematosus = Insights from Translational Research /

Record Type:	Language materials, printed : Monograph/item
Title/Author:	Pathogenesis of Systemic Lupus Erythematosus/ edited by Alberta Hoi.
Reminder of title:	Insights from Translational Research /
other author:	Hoi, Alberta.
Description:	XXI, 178 p. 36 illus., 24 illus. in color.online resource. :
Contained By:	Springer Nature eBook
Subject:	Immunology. -
Online resource:	https://doi.org/10.1007/978-3-030-85161-3
ISBN:	9783030851613

Pathogenesis of Systemic Lupus Erythematosus = Insights from Translational Research /
Pathogenesis of Systemic Lupus ErythematosusInsights from Translational Research /[electronic resource] :edited by Alberta Hoi. - 1st ed. 2021. - XXI, 178 p. 36 illus., 24 illus. in color.online resource.

Advances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.

The scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.

ISBN: 9783030851613

Standard No.: 10.1007/978-3-030-85161-3doiSubjects--Topical Terms:

592892
Immunology.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Pathogenesis of Systemic Lupus Erythematosus = Insights from Translational Research /
LDR:04132nam a22003975i 4500 001 1057151
003 DE-He213
005 20211115124524.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030851613 $9 978-3-030-85161-3
024 7 $a 10.1007/978-3-030-85161-3 $2 doi
035 $a 978-3-030-85161-3
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Pathogenesis of Systemic Lupus Erythematosus $h [electronic resource] : $b Insights from Translational Research / $c edited by Alberta Hoi.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a XXI, 178 p. 36 illus., 24 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Advances in translational science to identify new therapies for systemic lupus erythematosus -- Hallmark of systemic lupus erythematosus: Role of B Cell Hyperactivity. Fabien B Vincent, William A Figgett and Margaret L Hibbs -- B cell targeted therapies in systemic lupus erythematosus -- Type I Interferons and the perpetuation of a loss of tolerance -- Therapeutic Modulation of the Interferon Pathway in Systemic Lupus Erythematosus -- The concept of co-stimulatory blockade in SLE -- Cytokines: their role in amplifying SLE pathogenesis -- Intracellular targets in SLE -- Regulatory T cells in SLE -- Balancing strategies: GC and GILZ Axis.
520 $a The scope of this contributed volume is to provide an overview of the latest translational research in the field of lupus pathogenesis, with particular emphasis on how these discoveries progress in parallel with therapeutic drug development. Systemic lupus erythematosus (SLE) is a multifaceted disease with a number of well-defined immune pathways that are dysregulated, resulting in an immune-mediated chronic inflammatory injury at target organs. As knowledge of these pathways evolves to provide opportunities for targeted drug therapy and lays the foundation for personalized medicine, clinicians and researchers need to keep up with the ever-expanding medical literature. This book will critically appraise the current understanding of important immunological pathways that contribute to the pathogenesis of lupus. We will review the role of interferons as part of the innate immune defects that perpetuate the loss of self-tolerance in SLE. B cell hyperactivity, as a defining hallmark of SLE, and different strategies of B cell targeted therapy will be discussed. The role of co-stimulation or immune checkpoint molecules in activating B and T cells will be reviewed, as well as other cytokines that serve in the amplification loop promoting a more proinflammatory Th1 or Th17 responses. Intracellular targets, such as signaling molecules in the JAK/STAT pathway, or a variety of kinases and proteasomes, can cause a cascading downstream effect of transcriptional responses that are important in SLE. Immune homeostasis can also be restored by bolstering the naturally occurring anti-inflammatory mechanisms. Glucocorticoid, as a potent natural anti-inflammatory hormone, can mediate its effects by recruiting histone deacetylase that serve to repress gene transcription. Glucocorticoid-induced leucine zipper is a gene upregulated by glucocorticoid that can be a potential target for development of anti-inflammatory strategy. Finally, T regulatory cells can be utilized to help restore to immune tolerance and are amongst the latest focus of therapeutic development in SLE.
650 0 $a Immunology. $3 592892
650 0 $a Molecular biology. $3 583443
650 0 $a Cytokines. $3 581465
650 0 $a Growth factors. $3 872208
650 2 4 $a Molecular Medicine. $3 668353
650 2 4 $a Cytokines and Growth Factors. $3 787581
700 1 $a Hoi, Alberta. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1362564
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030851606
776 0 8 $i Printed edition: $z 9783030851620
776 0 8 $i Printed edition: $z 9783030851637
856 4 0 $u https://doi.org/10.1007/978-3-030-85161-3
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)